HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t1/2 = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t1/2 = 0.24 days). The estimated average total HIV-1 production was 10.3 × 109 virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time—defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles—is 2.6 days. These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.

[1]  N. Nathanson,et al.  Experimental infection of monkeys with Langat virus. II. Turnover of circulating virus. , 1967, American journal of epidemiology.

[2]  A. Dalgleish,et al.  Human retroviruses , 2014, Methods in Molecular Biology.

[3]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[4]  Isma'il ibn Ali al-Sadiq AIDS , 1986, The Lancet.

[5]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[6]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[7]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[8]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[9]  B. Irvine,et al.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[11]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[12]  Sebastian Bonhoeffer,et al.  HIV results in the frame , 1995, Nature.

[13]  D. Ho,et al.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.

[14]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[15]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[17]  E. Nestler,et al.  Opposite Modulation of Cocaine-Seeking Behavior by D1- and D2-Like Dopamine Receptor Agonists , 1996, Science.